Results 21 to 30 of about 20,731 (163)

Aztreonam Lysine Increases the Activity of Phages E79 and phiKZ against Pseudomonas aeruginosa PA01

Microorganisms, 2021
Pseudomonas aeruginosa is a pernicious bacterial pathogen that is difficult to treat because of high levels of antibiotic resistance. A promising alternative treatment option for such bacteria is the application of bacteriophages; the correct combination
Carly M. Davis, Jaclyn G. McCutcheon, Jonathan J. Dennis   +2 more
doaj   +1 more source

Recent Trends in Prostate Biopsy Complication Rates and the Role of Aztreonam in Periprocedural Antimicrobial Prophylaxis—A Nationwide Population-Based Study from Korea

Antibiotics, 2022
An increase in the rate of complications after prostate biopsy (PB) due to increased antibiotic-resistant bacteria is a global issue. We report the safety of aztreonam as a prophylactic antibiotic in patients undergoing PB.
Wook Nam, Min Uk Park, Han Kyu Chae, Jihye Song, Han Gwun Kim, Jong Yeon Park, Seokjoon Lee, Sung Jin Kim   +7 more
doaj   +1 more source

Genomic New Insights Into Emergence and Clinical Therapy of Multidrug-Resistant Klebsiella pneumoniae in Infected Pancreatic Necrosis

Frontiers in Microbiology, 2021
Infected pancreatic necrosis (IPN) is a key risk factor in the progression of severe acute pancreatitis, and use of antibiotics is one of the main clinical actions.
Haibin Hao, Yang Liu, Jin Cao, Kun Gao, Kun Gao, Yingying Lu, Yingying Lu, Weiping Wang, Peng Wang, Sida Lu, Long Hu, Zhihui Tong, Weiqin Li, Weiqin Li, Weiqin Li   +14 more
doaj   +1 more source

Aztreonam

Urology, 1993
Aztreonam is the first monobactam and is unique among beta-lactam antibiotics for its spectrum of activity that is exclusively active against gram-negative aerobic bacteria. Broad clinical experience with this agent supports its use in the treatment of adults with severe or complicated urologic infections.
openaire   +4 more sources

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review

Antibiotics, 2022
Objectives: The aim of this study was to describe our experience of a combination treatment including meropenem/vaborbactam (M/V) plus aztreonam (ATM) for bloodstream infections (BSIs) due to ceftazidime/avibactam-resistant Klebsiella pneumoniae (CAZ/AVI-
Alessandra Belati, Davide Fiore Bavaro, Lucia Diella, Nicolò De Gennaro, Francesco Di Gennaro, Annalisa Saracino   +5 more
doaj   +1 more source

In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model

Antibiotics, 2021
Carbapenem-resistant Enterobacterales (CRE) and carbapenemase-producing Enterobacterales (CPE) have become global threats. CRE− and CPE− derived infections have been associated with high mortality due to limited treatment options.
Mao Hagihara, Hideo Kato, Toshie Sugano, Hayato Okade, Nobuo Sato, Yuichi Shibata, Daisuke Sakanashi, Jun Hirai, Nobuhiro Asai, Hiroyuki Suematsu, Yuka Yamagishi, Hiroshige Mikamo   +11 more
doaj   +1 more source

Assessment of Safety Signals for Aztreonam in Different Age Groups: National and International Drug Safety Monitoring

Безопасность и риск фармакотерапии, 2022
Aztreonam is the only approved monocyclic β-lactam antibiotic for human use that is active against Gram-negative aerobes, primarily Pseudomonas аeruginosa. Aztreonam has been used for more than 35 years, and aztreonam lysine has been on the market for 15
E. A. Sokova, V. V. Arkhipov, A. S. Kazakov, B. K. Romanov, R. N. Alyautdin, M. V. Zhuravleva   +5 more
doaj   +1 more source

A Study on Ceftazidime/Avibactam and Aztreonam Synergy Among Aztreonam-resistant Metallo-β-lactamase Producing Enterobacterales in a Tertiary Care Hospital

Mediterranean Journal of Infection, Microbes and Antimicrobials
Introduction: Global detection of bacteria harboring metallo-β-lactamase (MBL) genes has increased at an alarming rate. However, there is no concurrent increase in available antibiotics for treatment, which has turned these infections into a public ...
Adelyn D’SOUZA, Rachana SHETTY, Asha Pai KB   +2 more
doaj   +1 more source

In vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases

Journal of Global Antimicrobial Resistance
Objectives: Infections caused by carbapenemase-producing Gram-negative pathogens have become a significant global public health challenge due to limited treatment options.
Kengo Hayashi, Masahiro Suzuki, Yoshikazu Ishii, Yasufumi Matsumura, Kazuaki Matsumoto, Sho Saito, Yohei Doi   +6 more
doaj   +1 more source

Antimicrobial Sensitivity Profile and Resistance Gene Research in Escherichia coli Isolated From Water and Fish From Lagoa da Conceição, Florianópolis, SC, Brazil

Food Safety and Health, EarlyView.
This paper highlights a concerning scenario of environmental contamination by multidrug‐resistant bacteria, underscoring the need for integrated surveillance and control strategies to address antimicrobial resistance in aquatic environments within the context of One Health.
Francisco Lucas de Amorim Nascimento, Luan Amaral Alexandre, Cynthia Farias Manassi, Alice Cristina da Silva, Luísa Aimée Schmitt Lobe, Gustavo Rocha, Mateus Rocha Ribas, Victor Wolleck, Gabriele Caroline Gottschalk de Abreu, Alessandra Valéria Vortmann, Sheila Mello da Silveira, Rodrigo Barcellos Hoff, Jussara Kasuko Palmeiro, Silvani Verruck   +13 more
wiley   +1 more source